Clinical trial
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the…
NCT00124215 · GlobeImmune, Industry · Completed
Key facts
| NCT number | NCT00124215 |
|---|---|
| Title | Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection |
| Official title | A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C… |
| Lead sponsor | GlobeImmune, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Biological |
| Interventions | GI-5005 |
| Enrollment | 48 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Feb 1, 2010 |
| First posted | Jul 27, 2005 |
| Last update posted | May 5, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: